shr-1707
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 23, 2021 (NCT04745104)
Timeline
Indications
Studied for
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06199037 | Phase 2 | Feb 5, 2024 | Hengrui Therapeutics, Inc. |
| NCT06114745 | Phase 1 | Jan 15, 2024 | Atridia Pty Ltd. |
| NCT05681819 | Phase 1 | Feb 17, 2023 | Hengrui Therapeutics, Inc. |
| NCT04973189 | Phase 1 | May 8, 2021 | Hengrui Therapeutics, Inc. |
| NCT04745104 | Phase 1 | Feb 23, 2021 | Atridia Pty Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2021 |
| Atridia Pty Ltd. | For profit | 2 | 2 | 1 | 2021 |
2 organizations
Page 1 / 1